Operating
Neurocrine Biosciences·Cash Flow Statement·17 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Net income | $65M | $129.8M | $103.1M | $7.9M | $107.5M | $209.5M | $153.7M | $197.9M |
| Net cash from operating activities | $64.6M | $158M | $242.5M | $64.8M | $102M | $227.5M | $388.4M | $145.8M |
| Change in income taxes payable/receivable | — | — | $55.1M | $15.4M | — | — | — | $119.8M |
| Change in accounts receivable | $17.6M | $12.9M | $0 | $36.9M | $79.7M | $132.3M | — | $81.4M |
| Deferred income taxes | -$41.3M | -$34.9M | -$31.3M | -$13.7M | -$37.4M | $168.3M | $48.2M | -$61.1M |
| Stock-based compensation | $43.1M | $41.5M | $66.4M | $52.8M | $52.8M | $53.7M | $58.6M | $57.2M |
| Gain (loss) on sale of assets | — | — | — | $0 | — | — | — | $28.6M |
| Net gains (losses) on investments | -$19.9M | -$16.9M | -$1.9M | -$30.6M | -$6.7M | $30.6M | — | $25.3M |
| Change in accounts payable | -$59.5M | $44.2M | $77.3M | -$3M | $30.9M | $55.8M | $76.5M | -$14.3M |
| Depreciation and amortization | $6.4M | $5.6M | $6.2M | $6.6M | $6.3M | $6.7M | $6.4M | $7.2M |
| Non-cash operating lease expense | — | $300K | — | $7.2M | $7.1M | $6.6M | — | $2.7M |
| Operating lease right-of-use asset amortization | — | $300K | — | $7.2M | $7.1M | $6.6M | — | $2.7M |
| Accretion (Amortization) of Discounts and Premiums, Investments | $7M | $6.5M | $5.6M | $4.6M | $3.4M | $2.7M | $2M | $1.3M |
| Amortization of intangible assets | $900K | $900K | $900K | $1M | $1M | $1M | $1.1M | $100K |
| Amortization of capitalized software and acquired intangible assets | $900K | $900K | $900K | $1M | $1M | $1M | $1.1M | $100K |
| Other working capital changes | -$3.4M | $0 | $100K | $700K | — | $200K | — | $0 |
| Non-cash lease expense | $2.6M | $2.6M | $2.6M | $6.7M | $6.7M | $6.7M | $6.7M | — |